Evidence map›Paper›PMID 28728309›Full record

ArticleAMB Express2017

Escherichia coli outer membrane protein F (OmpF): an immunogenic protein induces cross-reactive antibodies against Escherichia coli and Shigella.

Xiao Wang, Da Teng, Qingfeng Guan, Ruoyu Mao, Ya Hao, Xiumin Wang, Junhu Yao, Jianhua Wang

Open access · goldAbstract read
In one paragraph

Article in AMB Express, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Detection of immunoreactive proteins ofFrontiers in cellular and infection microbiology · 2023
    Article
  5. Novel Proteoliposome-Based Vaccine againstAnimals : an open access journal from MDPI · 2022
    Article
  6. Article
  7. BBA advances · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiao WangKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China.
Da TengKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China.
Qingfeng GuanKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China.
Ruoyu MaoKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China.
Ya HaoKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China.
Xiumin WangKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China. wangxiumin@caas.cn.
Junhu YaoCollege of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yaojunhu2004@sohu.com.
Jianhua WangKey Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, People's Republic of China. wangjianhua@caas.cn.
Chinese Academy of Agricultural Sciences · CNFeed Research Institute · CNNorthwest A&F University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diarrhea caused by pathogenic Escherichia coli (E. coli) is one of the most serious infectious diseases in humans and animals. Due to antibiotics resistance and the lack of efficient vaccine, more attention should be paid to find potential versatile vaccine candidates to prevent diseases. In this study, the sequence homology analysis indicated that OmpF from E. coli CVCC 1515 shares a high identity (90-100%) with about half of the E. coli (46.7%) and Shigella (52.8%) strains. Then the recombinant OmpF was supposed to be developed as a versatile vaccine to prevent E. coli infection. OmpF was expressed in E. coli BL21 (DE3) using the auto-induction method. The recombinant OmpF (rOmpF) protein had an average molecular weight of 40 kDa with the purity of 90%. Immunological analysis indicated that the titers of anti-rOmpF sera against rOmpF and whole cells were 1:240,000 and 1:27,000, respectively. The opsonophagocytosis result showed that 72.21 ± 11.39 and 11.04 ± 3.90% of bacteria were killed in the rOmpF immunization and control groups, respectively. The survival ratio of mice immunized with rOmpF ranged between 40 and 60% as observed within 36 h after challenge, indicating mice were partially protected from E. coli CVCC 1515 infection. The expressed rOmpF protein induced an effective immune response, but only provide a weak protection against pathogenic E. coli CVCC 1515 and a small reduction in E. coli CICC 21530 (O157:H7) excretion in a mouse infection model. Native forms of the OmpF antigen may be studied for immunogenicity and potential protective efficacy.

Indexed as

Escherichia coliImmune protectionMiceRecombinant OmpFVaccine

Identifiers

PMID28728309
PMCPMC5517391
OpenAlexW2736932263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.